What it means
Individual biotech investing is unforgiving: one failed trial can erase most of a single company's value overnight. A biotech ETF spreads that risk across dozens or hundreds of companies.
The fund tracks an index of biotech shares or follows an active strategy, and investors buy and sell units of the whole basket through any brokerage account, gaining sector exposure without picking winners. These funds share the standard ETF mechanics with a few sector-specific traits.
Holdings range from large, profitable biotech firms to small developers with no revenue, and funds weight them by market value, equally, or by rules such as liquidity screens. Expense ratios are typically higher than broad market funds because the sector is specialised.
Pricing stays close to the value of the underlying shares through the creation and redemption process, where large institutions exchange baskets of shares for fund units. For managers and investors, the trade-offs are concentration and character.
A biotech ETF still swings hard, because the whole sector reacts to interest rates, trial news, and regulation, so it diversifies single-company risk but not sector risk. Some funds are dominated by a few large holdings, which quietly reintroduces concentration.
Reading the fund's weighting method, top holdings, and expense ratio tells you what you actually own. Choosing between funds takes more than comparing tickers.
Beyond the weighting method, check the average daily trading volume and bid-ask spread, since a thinly traded fund costs more to enter and exit than its expense ratio suggests. Tracking difference, the gap between the fund's return and its index's, reveals hidden drag from fees, sampling, and securities lending.
Investors who already own a broad market fund should also check overlap: the largest biotech companies sit inside major indices, so a biotech ETF can quietly double a position they already hold.
In practice
Real-world examples.
Example
An investor buys shares of a biotech ETF tracking an index of 150 companies, gaining sector exposure for an annual expense ratio below 1%. The purchase settles like any share trade, with no minimum investment beyond one unit's price.
Example
A market-cap-weighted biotech fund rises mostly on strong results from its three largest holdings, which together make up a third of the portfolio. Investors who assumed they owned 150 equal bets find that a handful of names drove the return.
Example
During a sector sell-off after a drug-pricing announcement, a biotech ETF falls 8% in a week even though no single holding reported bad news. A cautious investor checks the fund's daily premium or discount to net asset value before placing a large order.
Formula
Calculation
ETF net asset value = total market value of holdings / units outstanding. Market price tracks NAV through arbitrage, and the fund's return roughly equals the index return minus the expense ratio.
Worked example. A biotech ETF holds shares worth $500,000,000 and has 10,000,000 units outstanding.
- NAV per unit = $500,000,000 / 10,000,000 = $50.00.
- If the units trade at $50.25, the premium is $0.25 / $50.00 = 0.5%, and large institutions can profit by creating new units until the gap closes.
- If the tracked index returns 12% in a year and the expense ratio is 0.45%, the fund returns roughly 12% - 0.45% = 11.55%, so an investor with $20,000 in the fund pays about $20,000 x 0.0045 = $90 a year in fees.Case study
Seen in the real world.
This fictional, illustrative example follows Anaya, finance director at an invented manufacturer called Corvella. She wanted biotech exposure for her personal portfolio but knew she could not judge trial data. She compared two funds: one weighted by market value, with 40% in five large companies, and an equal-weighted alternative spreading risk evenly across eighty names. She chose the equal-weighted fund for broader diversification, accepted its higher expense ratio, and capped the position at 5% of her portfolio. When a mid-cap holding doubled on trial results and another collapsed the same quarter, the fund's value moved less than 3%, exactly the smoothing she wanted.
She also confirmed the fund lent out only a small share of its holdings, keeping the counterparty risk of securities lending within her comfort level. Her sizing logic was simple. On a $400,000 portfolio, a 5% position is $20,000, so even a 40% fall in the fund would cost $8,000, which is 2% of her total wealth. The people and figures are invented.
Watch out
Common mistakes.
- Believing a biotech ETF removes volatility, when it diversifies single-company trial risk but leaves full exposure to sector-wide swings.
- Skipping the weighting method, since a market-cap-weighted fund can be dominated by a handful of large holdings.
- Comparing funds only on past returns while ignoring expense ratios, holdings overlap, and how closely each fund tracks its index.
Questions
People also ask.
Why choose a biotech ETF over individual stocks?
It spreads the binary trial risk that makes single biotech stocks so dangerous, giving diversified sector exposure through one ordinary brokerage purchase.
What does market-cap versus equal weighting change?
Market-cap weighting concentrates the fund in the largest companies, while equal weighting spreads exposure evenly, giving smaller companies more influence on returns.
Is a biotech ETF a low-risk investment?
No. It is lower risk than owning one or two biotech stocks, but the sector as a whole remains volatile and sensitive to rates, regulation, and trial news. Neither is automatically better; the choice depends on whether you want the stability of the giants or the torque of the smaller developers.
From the founder's library
Take it further with the book.
Build your financial confidence beyond this definition. Shihan's full-length guide, Accounting Fundamentals, takes the same plain-English approach and turns it into a complete, practical playbook for non-finance managers, business owners and students - with chapter-end quiz answers and presentation slides included.
25% off with code MMHQ25, applied at checkout. Priced in USD - checkout may show the equivalent in your local currency.
View the book and save 25%Related